JMI Laboratories, North Liberty, Iowa, USA; University of Iowa, Iowa City, Iowa, USA.
JMI Laboratories, North Liberty, Iowa, USA.
Diagn Microbiol Infect Dis. 2019 Jul;94(3):304-313. doi: 10.1016/j.diagmicrobio.2019.01.015. Epub 2019 Jan 26.
Ceftobiprole medocaril, the prodrug of ceftobiprole, is an advanced-generation cephalosporin that is approved in many European and non-European countries for the treatment of adults with hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia and is currently being evaluated in a global phase 3 clinical trial of patients with Staphylococcus aureus bacteremia. This study investigated the in vitro activity of ceftobiprole and comparators against a total of 5466 gram-positive and -negative isolates from bloodstream infections (BSIs) that were collected in the United States during 2016 and 2017 as part of the SENTRY Antimicrobial Surveillance Program. Ceftobiprole was highly active (isolates were >99% susceptible) against S. aureus (including methicillin-resistant S. aureus), coagulase-negative staphylococci, Enterococcus faecalis, streptococci, and non-extended-spectrum β-lactamase (non-ESBL) phenotype Enterobacteriaceae. As expected, lower activities were observed against Enterococcus faecium, ESBL-phenotype Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. These results support further clinical evaluation of ceftobiprole for the treatment of BSIs caused by susceptible organisms.
头孢托罗匹酯甲磺酸盐是头孢托罗的前体药物，是一种新型头孢菌素，已在许多欧洲和非欧洲国家获得批准，用于治疗成人医院获得性肺炎（不包括呼吸机相关性肺炎）和社区获得性肺炎，目前正在一项全球 3 期临床试验中评估其治疗金黄色葡萄球菌菌血症患者的疗效。本研究调查了头孢托罗匹酯及其对照药物对 2016 年至 2017 年期间作为 SENTRY 抗菌监测计划的一部分在美国采集的共 5466 株血流感染（BSI）革兰阳性和革兰阴性分离株的体外活性。头孢托罗匹酯对金黄色葡萄球菌（包括耐甲氧西林金黄色葡萄球菌）、凝固酶阴性葡萄球菌、粪肠球菌、链球菌和非扩展谱β-内酰胺酶（非 ESBL）表型肠杆菌科具有高度活性（分离株的药敏率均＞99%）。如预期的那样，对屎肠球菌、ESBL 表型肠杆菌科、铜绿假单胞菌和鲍曼不动杆菌的活性较低。这些结果支持进一步评估头孢托罗匹酯治疗敏感菌引起的血流感染的临床应用。
